Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Encorafenib + Cetuximab +/- Alpelisib in BRAF Mutant Metastatic Colorectal Cancer
NCT01719380Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2012
- Primary completion
- Oct 2015
- Modality
- Small Molecules
- Countries
- 12
01
Overview
Phase 2, randomised, open-label trial of encorafenib in colorectal cancer (CRC) (2 arms), sponsored by Pfizer. Primary endpoints: Incidence of Dose Limiting Toxicities and Progression Free Survival up to 43 months. Started Nov 2012; status: completed.
02
Drugs
encorafenib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01719380.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01719380.